NASDAQ:SCYX
SCYNEXIS Stock News
$2.41
+0.150 (+6.64%)
At Close: May 16, 2024
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q1 2022 Results - Earnings Call Transcript
01:34pm, Thursday, 12'th May 2022
SCYNEXIS, Inc. (NASDAQ:SCYX ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Marco Taglietti – President and Chief Executive Officer Christine Coyne – Chief Commerci
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
12:35pm, Thursday, 12'th May 2022 Zacks Investment Research
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
09:47am, Thursday, 12'th May 2022
Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 years Product theater presentation will be held
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
09:18pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded w
Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections
03:15pm, Friday, 22'nd Apr 2022
SCYNEXIS Inc (NASDAQ: SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients w
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
12:15pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants.
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
12:00pm, Friday, 22'nd Apr 2022 GlobeNewswire Inc.
JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resis
Why Scynexis Shares Are Falling During Thursday's After-Hours Session
05:21pm, Thursday, 21'st Apr 2022
SCYNEXIS Inc (NASDAQ: SCYX) shares are trading lower after the company announced a public offering of common stock. The size of the offering was not disclosed.
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
12:30pm, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
Data from studies evaluating ibrexafungerp in serious fungal infections will be presented Data from studies evaluating ibrexafungerp in serious fungal infections will be presented
Data from studies evaluating ibrexafungerp in serious fungal infections will be presented Data from studies evaluating ibrexafungerp in serious fungal infections will be presented
SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences
01:59pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resis
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call Transcript
02:09pm, Tuesday, 29'th Mar 2022
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call Transcript
Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Scynexis (SCYX) delivered earnings and revenue surprises of -47.89% and 53.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?